JPM 2025: Sidley’s Meena Datta on Potential Headwinds for the Life Sciences Industry
JPM 2025: Sidley’s Rebecca Wood and Emily Marden on their FDA Outlooks for 2025
Connecting Clusters of Excellence @ JPM 2025 | Unlocking Investment and Deal Opportunities in Europe with Sidley’s Robert Darwin
JPM 2025: Sidley’s Geoff Levin on Trends in Biotech and Biopharma in 2025
JPM 2025: Sidley’s James Lu and Josh Hofheimer on Cross-Border Investment Opportunities in 2025